Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

OBJECTIVE: To evaluate the efficacy and safety of adalimumab plus methotrexate (MTX) given for up to 4 years in patients with active, longstanding rheumatoid arthritis. METHODS: Patients responding inadequately to MTX were entered into a 24 week, controlled study (ARMADA) with adalimumab plus MTX or...

Full description

Saved in:
Bibliographic Details
Main Authors: Weinblatt, M E, Keystone, E C, Furst, D E, Kavanaugh, A F, Chartash, E K, Segurado, O G
Format: Artigo
Language:Inglês
Published: BMJ Group 2006
Subjects:
Extended Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1798163/
https://ncbi.nlm.nih.gov/pubmed/16308341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2005.044404
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items